Tri-county hospitals oppose Trump health care bill
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Gene technology raises ethical questions
By Frank Kalman A relatively obscure talk about genes was given at UC Santa Barbara recently by Dr. Siddhartha Mukherjee, a researcher and clinical oncologist at Columbia University and author of a Pulitzer Prize winning book, the “Emperor of all Maladies: A Biography of Cancer.” It was, however, on par in terms of gravity with Read More →
Agilent cancer treatment approved in Europe
Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
Patent ruling in favor of Amgen has shares skyrocketing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Elings donates $4 million to Cancer Center of Santa Barbara
Philanthropist Virgil Elings donated $4 million to the new Cancer Center of Santa Barbara to open in the fall at 540 W. Pueblo St. The $53 million cancer center, which merged with Sansum Clinic in 2012, will be renamed the Ridley-Tree Cancer Center to honor Lady Leslie Ridley-Tree’s $10.73 million donation. The Elings Oncology Building Read More →
Amgen buying rights to Advaxis cancer treatment
Thousand Oaks-based biotech giant Amgen said it will buy the rights to develop and commercialize a cancer immunotherapy treatment Aug. 2. Under the agreement, Amgen will pay Princeton, N.J.-based Advaxis $40 million and buy $25 million worth of Advaxis common stock for the rights to develop and commercialize a preclinical cancer immunotherapy, which is designed Read More →
